Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?
Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Most importantly a genetic polymorphism in the gene encoding for the complement factor H (CFH) has been recently identified which is highly associated with an increased risk of developing AMD. This Tyr402His polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease.
For this purpose a total of 200 patients with wet AMD will be included in the study. As described in detail below, the current study aims to identify potentially non-responders to anti-VEGF therapy based on genetic analysis of VEGF polymorphism and complement factor H polymorphism.
|Choroidal NeoVascularization Age-Related Macular Degeneration||Genetic: VEGF genotyping|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Does VEGF or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With CNV?|
- Visual acuity using ETDRS charts [ Time Frame: 2 x 5 minutes ]
- Central retinal thickness (Optical coherence tomography) [ Time Frame: 2 x 20 minutes ]
- VEGF genotyping [ Time Frame: 1 week ]
|Study Start Date:||January 2009|
|Study Completion Date:||November 2014|
|Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
Open longitudinal study with observer masked analysis
Genetic: VEGF genotyping
blood sample for gene analysis
Please refer to this study by its ClinicalTrials.gov identifier: NCT00813514
|Department of Clinical Pharmacology, Medical University of Vienna|
|Principal Investigator:||Leopold Schmetterer, Prof. Dr.||Department of Clinical Pharmacology|